Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

AGM Statement

11 Jun 2014 07:00

RNS Number : 3118J
Sopheon PLC
11 June 2014
 



SOPHEON PLC

 

AGM Statement

 

At the Annual General Meeting of Sopheon plc to be held later today, the chairman of the board will give shareholders an update and review of the business. This will include the following statement:

 

"After a very solid performance in 2012, we were pleased to report another year of growth in 2013 with revenues rising to £13.3m. Profitability continued to improve as well, with EBITDA at £1.9m and profit before tax £341,000. Our focus on vertical markets resulted in several new license wins with consumer goods companies. Our work with major consulting partners also continued to gather pace. Sopheon's agile development methodology resulted in two milestone software releases with Accolade 8.3 and 9.0. Furthermore, a number of corporate milestones were progressed in 2013; we secured court approval for a capital reduction, reducing the deficit on the Group's accumulated reserves and we implemented a share consolidation which reduced the number of shares in issue by a ratio of 20:1 and decreased the number of very small shareholdings by over 5,000.

 

As we first predicted some years ago, we believe the market in which Sopheon operates is shifting to one that is more operationally critical, with higher exposure to senior management, just as ERP and CRM shifted in earlier times. Interactions with customers such as PepsiCo, BASF, SABIC and Philips, and coverage from analysts such as Gartner, demonstrate rising acknowledgement that innovation is becoming an enterprise level priority, which requires enterprise level software. We are also seeing and participating in the first conferences aimed directly at Chief Innovation Officers. This changing environment can lead to more phased multi-year client relationships with elongated revenue profiles - but with greater and more strategic long term potential. Since the start of the year we have brought new blood into our US sales team in part to reflect these trends in the market. We are particularly pleased to announce Sheila Plunkett as the US vice president of sales. Sheila joined us in April and has extensive experience gained from both large companies such as IBM, E&Y and SAP as well as small start-up software companies, building a record of developing enterprise sales teams that deliver results.

 

At this time last year, we noted that we were working to close a considerable amount of license business, some of which was needed in June to enable first half revenues to exceed those in the equivalent period in 2012. Last year, we managed to achieve that goal. Revenue visibility today again stands above £8m, comparable to a year ago; and there are again plenty of deals we are striving to close by the end of June. However, looking at the current sales pipeline, and the recognition profile of closed business, we expect that revenues in 2014 will be heavily weighted to the second half of the year. As we have always emphasised, the actual timing and value of individual sales events can have a substantial impact on reported performance for a given period, as can the market developments and sales team changes mentioned above.

 

Looking beyond sales and operations, the high pitch of product release has continued during the last six months, with the release of Accolade® 9.1 in April, advancing our enterprise portfolio and planning capabilities. We have continued to work on our corporate restructuring program, negotiating $3.5m in new debt facilities with Silicon Valley Bank, at lower interest cost, and more recently we have secured agreement to extend the maturity of our convertible loan note by an additional two years. However, as noted before, incorrect processing of our share consolidation by certain Netherlands market participants means that the board is planning to repeat the procedure, and our current plan is to do this after publication of our interim results. Also unfortunate was Euronext's decision to wind down the Alternext Amsterdam segment, relatively soon after we were encouraged to join it. Options available to Sopheon include a transfer of our listing back to the Euronext Amsterdam main market, a transfer to Alternext Paris or Brussels, or a consolidation solely onto our primary AIM listing in London. We will continue to explore all alternatives and will inform shareholders accordingly."

 

For further information contact:

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Charlotte Stranner / Victoria Bates

finnCap

+ 44 (0) 20 7600 1658

Heather Armstrong

Newgate Threadneedle

+ 44 (0) 20 7653 9842

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Performance solutions including software, expertise, and best-practices to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade® solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle. For the first time, businesses can access a single source of the truth across strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM at the London Stock Exchange and on the Alternext Exchange in the Netherlands. For more information, please visit www.sopheon.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMLLFERRIIILIS
Date   Source Headline
27th Jan 20117:00 amPRNTrading Statement
9th Dec 20107:00 amPRNAmendment to the Terms of Convertible Loan Stock
16th Nov 20107:00 amPRNContract Win
4th Nov 20107:00 amPRNInterim Management Statement
27th Aug 201010:30 amPRNGrant of Options
26th Aug 20107:00 amPRNHalf-yearly Report
22nd Jul 20107:00 amRNSTrading Update
15th Jun 20105:31 pmPRNResult of AGM
15th Jun 20107:00 amPRNAGM Statement
18th May 20107:00 amRNSAfton Chemical Selects Idea Lab
6th May 20107:00 amPRNInterim Management Statement
25th Mar 20107:00 amPRNFinal Results
22nd Mar 20107:00 amRNSiSUSTAINT Alliance Launched
3rd Feb 20107:00 amRNSSopheon Team wins TARDEC Contract
28th Jan 20107:00 amPRNTrading Update
24th Dec 20097:01 amRNSExtension of GEM Equity Line
2nd Dec 20097:00 amRNSVision Strategist Version 5.0 Launched
3rd Nov 20097:00 amPRNInterim Management Statement
2nd Oct 20093:43 pmPRNISSUE OF CONVERTIBLE LOAN STOCK
27th Aug 20097:00 amPRNHalf-yearly Report
16th Jun 200912:34 pmPRNResult of AGM
16th Jun 20097:00 amPRNAGM Statement
19th May 20097:00 amPRNProduct Launch
7th May 20097:00 amPRNInterim Management Statement
26th Mar 20097:00 amPRNFinal Results
18th Mar 20097:00 amRNSBostik Implements Sopheon's Accolade System
11th Mar 20097:00 amRNSContract Win
11th Feb 20097:00 amRNSEnhanced Version of Accolade? Launched
28th Jan 20097:00 amPRNTrading Update
21st Jan 20097:00 amRNSSopheon Partners with Maxsoft
4th Nov 20087:00 amPRNInterim Management Statement
28th Aug 20087:00 amPRNHalf-yearly Report
27th Jun 20083:47 pmPRNDirector/PDMR Shareholding
25th Jun 20087:00 amPRNGrowth Milestone
10th Jun 20087:00 amPRNAGM Statement
16th May 20087:00 amPRNDirector/PDMR Shareholding
15th May 20087:00 amPRNInterim Management Statement
6th May 200810:00 amPRNNotice of AGM
29th Apr 20087:02 amRNSContract Win
1st Apr 200810:00 amPRNGrant of Options
27th Mar 20087:00 amPRNFinal Results
6th Feb 20087:01 amRNSProduct Development
25th Jan 20087:00 amPRNTrading Update
21st Dec 200710:30 amPRNTrading Update
25th Oct 20077:00 amPRNTrading Update
16th Oct 20072:38 pmBUSBeiersdorf Implements Sopheon System in Support of Product Innovation Strategy
16th Oct 20077:01 amRNSContract Win
10th Oct 20072:45 pmBUSLeading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System
10th Oct 20077:01 amRNSContract Win
1st Oct 20077:02 amRNSContract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.